The Ebola virus consists of small but lethal filament of RNA containing only seven genes. CDC Today, CNN is reporting that the two US citizens who were flown back to the states after contracting Ebola virus were given an extremely experimental treatment, one that’s still undergoing animal testing. While the treatment involves antibodies, it’s not a vaccine and can work effectively even after an infection has started. The process that produced it is a testament to the impressive capabilities developed in the field of biotechnology. The Ebola virus, known for its horrific symptoms and high fatality rate, currently has no established treatment. Which means that health care workers who are fighting the disease, and thus at high risk for becoming infected themselves, can do little more than put themselves in isolation and try to compensate for the damage the virus causes. That was apparently the case for two Americans who contracted the virus while working in Liberia. In this case, however, both were apparently given an experimental treatment developed in part by a company called Mapp Biopharmaceutical. Complicating matters, Mapp licenses its developments to a company called LeafBio for production and distribution. But LeafBio has also licensed an Ebola treatment from a second company, called Defyrus, and plans on combining the two. It’s unclear whether the Americans received the original or combined therapy. In either case, both therapies were based on the same developmental process outlined below. Read 9 remaining paragraphs | Comments
View original post here:
Bio-high-tech treatment for Ebola may have saved two US citizens
